ConductScience.org, home

Paper25706232

Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.

Osinusi A and 27 others. JAMA, 2015. Cited by 167 papers, by iCite.

Cite this record

ConductScience Library. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. Papers, record 25706232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25706232

Download JSON
Disease
HIV infectious disease454 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.
PubMed
Journal
JAMA
PubMed
Year
2015
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
167
iCite
Relative citation ratio, by iCite
6.45
iCite
Revised in PubMed
2025-05-29
PubMed

Authors28

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Osinusi AAnu
2Townsend KKerry
3Kohli AAnita
4Nelson AAmy
5Seamon CCassie
6Meissner EGEric G
7Bon DDimitra
8Silk RRachel
9Gross CChloe
10Price AAngie
11Sajadi MMohammad
12Sidharthan SSreetha
13Sims ZZayani
14Herrmann EEva
15Hogan JJohn
16Teferi GGebeyehu
17Talwani RRohit
18Proschan MMichael
19Jenkins VVeronica
20Kleiner DEDavid E

Source PubMed

See all 28 authorsDownload CSV of authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antiviral AgentsMajor topic
BenzimidazolesMajor topic
FluorenesMajor topic
HIV InfectionsMajor topic
HepacivirusMajor topic
Hepatitis C, ChronicMajor topic
Uridine MonophosphateMajor topic
Administration, Oral
Adult
Coinfection
Drug Therapy, Combination
Female
Genotype
Humans
Male
Middle Aged
Myalgia
RNA, Viral
Sofosbuvir
Treatment Outcome
Viral Load

Source PubMed

Download CSV of topics

Grants7

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
Z01 BC010686Intramural NIH HHSUnited StatesZ01BC010686PubMedNIH RePORTER
Z01 AI000390Intramural NIH HHSUnited StatesZ01AI000390PubMedNIH RePORTER
ZID BC011242Intramural NIH HHSUnited StatesZIDBC011242PubMed and NIHNIH RePORTER
HHSN261200800001CCCR NIH HHSUnited StatesPubMedPubMed
HHSN261200800001ENCI NIH HHSUnited StatesPubMedPubMed
ZIACL009010NIHNIH RePORTER
ZIACL040015NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01878799Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIVDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections3

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in25705993Hepatitis C and HIV co-infection: closing the gaps.https://conductscience.org/library/papers/25705993PubMed
Comment in26172899Drug-Drug Interactions in Patients Co-infected With HCV and HIV.https://conductscience.org/library/papers/26172899PubMed
Comment in26172900Drug-Drug Interactions in Patients Co-infected With HCV and HIV--Reply.https://conductscience.org/library/papers/26172900PubMed

Download CSV of comments and corrections

References23

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
124725238Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.N Engl J Med2014https://conductscience.org/library/papers/24725238PubMed
219684573Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.Nature2009https://conductscience.org/library/papers/19684573PubMed
322820790Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV.JAMA2012https://conductscience.org/library/papers/22820790PubMed
423291588A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.Nat Genet2013https://conductscience.org/library/papers/23291588PubMed
523685940Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial.Ann Intern Med2013https://conductscience.org/library/papers/23685940PubMed
619414839A new equation to estimate glomerular filtration rate.Ann Intern Med2009https://conductscience.org/library/papers/19414839PubMed
720831874Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.J Theor Biol2010https://conductscience.org/library/papers/20831874PubMed
823982366Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.JAMA2013https://conductscience.org/library/papers/23982366PubMed
920723038A perspective on modelling hepatitis C virus infection.J Viral Hepat2010https://conductscience.org/library/papers/20723038PubMed
1016908797Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.Arch Intern Med2006https://conductscience.org/library/papers/16908797PubMed
1124720702Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.N Engl J Med2014https://conductscience.org/library/papers/24720702PubMed
1215282352Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.N Engl J Med2004https://conductscience.org/library/papers/15282352PubMed
1323768747Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.Lancet Infect Dis2013https://conductscience.org/library/papers/23768747PubMed
1423390302Current management of hepatitis C virus infection in patients with HIV co-infection.J Infect Dis2013https://conductscience.org/library/papers/23390302PubMed
1515598915Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.JAMA2004https://conductscience.org/library/papers/15598915PubMed
1615282351Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.N Engl J Med2004https://conductscience.org/library/papers/15282351PubMed
1725192745Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.Clin Infect Dis2014https://conductscience.org/library/papers/25192745PubMed
1824725239Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.N Engl J Med2014https://conductscience.org/library/papers/24725239PubMed
1923172780Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.Hepatology2013https://conductscience.org/library/papers/23172780PubMed
2023499158
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
Lancet Infect Dis2013https://conductscience.org/library/papers/23499158PubMed

See all 23 referencesDownload CSV of references

Cited by99

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 167 citations.

PMIDTitleJournalYearIn PapersSource
41018711Changes in Bone Microarchitecture and Inflammatory Cytokines After Cure of Chronic Hepatitis C Infection With Direct-Acting Antiviral Therapy.Open Forum Infect Dis2025https://conductscience.org/library/papers/41018711PubMed
40006924Hepatitis C Virus Resistance-Associated Substitutions in Mexico.Viruses2025https://conductscience.org/library/papers/40006924PubMed
36777459Effect of Direct Antiviral Therapy Against HCV on CD4+ T Cell Count in Patients with HIV-HCV Coinfection.HIV AIDS (Auckl)2023https://conductscience.org/library/papers/36777459PubMed
36562643Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co-infection.J Int AIDS Soc2022https://conductscience.org/library/papers/36562643PubMed
36514496Treatment outcomes and costs of a simplified antiretroviral treatment strategy for hepatitis C among Hepatitis C Virus and Human Immuno deficiency Virus co-infected patients in Ukraine.JGH Open2022https://conductscience.org/library/papers/36514496PubMed
36233234Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects.Int J Mol Sci2022https://conductscience.org/library/papers/36233234PubMed
35334612Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users.Medicina (Kaunas)2022https://conductscience.org/library/papers/35334612PubMed
34845874Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea.J Korean Med Sci2021https://conductscience.org/library/papers/34845874PubMed
34222417Current treatment for hepatitis C virus/human immunodeficiency virus coinfection in adults.World J Clin Cases2021https://conductscience.org/library/papers/34222417PubMed
34205966Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?Viruses2021https://conductscience.org/library/papers/34205966PubMed
34157923An evaluation of ledipasvir + sofosbuvir for the treatment of chronic hepatitis C infection.Expert Opin Pharmacother2021https://conductscience.org/library/papers/34157923PubMed
33871393Well tolerability and highly effective treatment response for hepatitis C virus-human immunodeficiency virus-coinfected patients treated by all-oral direct-acting antivirals.J Chin Med Assoc2021https://conductscience.org/library/papers/33871393PubMed
33072543Efficacy of Sovodak in the Management of Patients Co-infected with HIV/HCV.Adv Pharm Bull2020https://conductscience.org/library/papers/33072543PubMed
33050486Lymphocyte Landscape after Chronic Hepatitis C Virus (HCV) Cure: The New Normal.Int J Mol Sci2020https://conductscience.org/library/papers/33050486PubMed
32915202
DNA Methylation and Immune Cell Markers Demonstrate Evidence of Accelerated Aging in Patients with Chronic Hepatitis B Virus or Hepatitis C Virus, with or without Human Immunodeficienct Virus Co-infection.
Clin Infect Dis2021https://conductscience.org/library/papers/32915202PubMed
32308542Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges.Int J Med Sci2020https://conductscience.org/library/papers/32308542PubMed
31922124Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis.EClinicalMedicine2020https://conductscience.org/library/papers/31922124PubMed
31504644Metabolic Changes in Chronic Hepatitis C Patients Who Carry IFNL4-ΔG and Achieve Sustained Virologic Response With Direct-Acting Antiviral Therapy.J Infect Dis2020https://conductscience.org/library/papers/31504644PubMed
31413526Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions.World J Gastroenterol2019https://conductscience.org/library/papers/31413526PubMed
31114268Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial.Infect Drug Resist2019https://conductscience.org/library/papers/31114268PubMed

See all 99 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
IFNL3282617PubTator's text mininghttps://conductscience.org/library/genes/282617NCBI Gene
IFNL4101180976PubTator's text mininghttps://conductscience.org/library/genes/101180976NCBI Gene

Download CSV of genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
SOFOSBUVIRCHEMBL1259059Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1259059ChEMBL
LEDIPASVIRCHEMBL2374220Derived from the trial1https://conductscience.org/library/drugs/CHEMBL2374220ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25706232

GET https://conductscience.org/api/papers/v1/25706232/authors?page=2